522 related articles for article (PubMed ID: 17916982)
1. Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up.
Tarr T; Lakos G; Bhattoa HP; Soltesz P; Shoenfeld Y; Szegedi G; Kiss E
Clin Rev Allergy Immunol; 2007 Apr; 32(2):131-7. PubMed ID: 17916982
[TBL] [Abstract][Full Text] [Related]
2. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients.
Tarr T; Lakos G; Bhattoa HP; Shoenfeld Y; Szegedi G; Kiss E
Lupus; 2007; 16(1):39-45. PubMed ID: 17283584
[TBL] [Abstract][Full Text] [Related]
3. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests.
Day HM; Thiagarajan P; Ahn C; Reveille JD; Tinker KF; Arnett FC
J Rheumatol; 1998 Apr; 25(4):667-74. PubMed ID: 9558167
[TBL] [Abstract][Full Text] [Related]
5. Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?
Uludağ Ö; Çinar S; McDonnell T; Çene E; Yalçinkaya Y; Gül A; Inanç M; Artim Esen B
Turk J Med Sci; 2023; 53(5):1067-1074. PubMed ID: 38813003
[TBL] [Abstract][Full Text] [Related]
6. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus.
İlgen U; Yayla ME; Ateş A; Okatan İE; Yurteri EU; Torgutalp M; Keleşoğlu ABD; Turgay TM; Kınıklı G
Lupus; 2018 Apr; 27(4):665-669. PubMed ID: 29050535
[TBL] [Abstract][Full Text] [Related]
7. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies.
Cabiedes J; Cabral AR; Alarcón-Segovia D
J Rheumatol; 1995 Oct; 22(10):1899-906. PubMed ID: 8991989
[TBL] [Abstract][Full Text] [Related]
8. Subsequent Thrombotic Outcomes in Patients with Ischemic Stroke with Antiphospholipid Antibody Positivity.
Pyo JY; Jung SM; Lee SW; Song JJ; Lee SK; Park YB
Yonsei Med J; 2017 Nov; 58(6):1128-1134. PubMed ID: 29047236
[TBL] [Abstract][Full Text] [Related]
9. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study.
Mustonen P; Lehtonen KV; Javela K; Puurunen M
Lupus; 2014 Dec; 23(14):1468-76. PubMed ID: 25164304
[TBL] [Abstract][Full Text] [Related]
10. Prevalence, outcome and management of patients with SLE and secondary antiphospholipid antibody syndrome after aPL seroconversion.
Zen M; Loredo Martinez M; Benvenuti F; Gatto M; Saccon F; Larosa M; Iaccarino L; Doria A
Rheumatology (Oxford); 2021 Mar; 60(3):1313-1320. PubMed ID: 32940703
[TBL] [Abstract][Full Text] [Related]
11. Antiphospholipid antibodies in patients with COVID-19: A relevant observation?
Devreese KMJ; Linskens EA; Benoit D; Peperstraete H
J Thromb Haemost; 2020 Sep; 18(9):2191-2201. PubMed ID: 32619328
[TBL] [Abstract][Full Text] [Related]
12. Relevance of non-criteria antiphospholipid antibodies titers among patients with antiphospholipid syndrome and patients with systemic lupus erythematosus.
Urrego-Callejas T; Hernández A; Ruiz Giraldo S; Frade-Sosa B; Vanegas-García AL; Muñoz CH; Rua C; Duque Botero J; González LA; Vásquez G; Gómez-Puerta JA
Reumatol Clin (Engl Ed); 2023 Apr; 19(4):197-203. PubMed ID: 37061281
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of antibodies to beta2-glycoprotein 1 from patients with systemic lupus erythematosus.
Cabral AR; Cabiedes J; Alarcón-Segovia D
Lupus; 2004; 13(3):182-7. PubMed ID: 15119547
[TBL] [Abstract][Full Text] [Related]
14. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.
Tektonidou MG; Sotsiou F; Nakopoulou L; Vlachoyiannopoulos PG; Moutsopoulos HM
Arthritis Rheum; 2004 Aug; 50(8):2569-79. PubMed ID: 15334471
[TBL] [Abstract][Full Text] [Related]
15. [Antiphospholipid syndrome and stroke].
Kitagawa Y
Rinsho Shinkeigaku; 2005 Nov; 45(11):852-5. PubMed ID: 16447744
[TBL] [Abstract][Full Text] [Related]
16. [Antibodies to various phospholipids in SLE patients with primary antiphospholipid syndrome].
Reshetniak TM; Boĭtsekhovskaia B; Alekberova ZS; Kalashnikova LA; Mach ES; Zabek Ia
Klin Med (Mosk); 1999; 77(5):32-7. PubMed ID: 10394784
[TBL] [Abstract][Full Text] [Related]
17. Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) Among Patients With Antiphospholipid Antibodies (aPL).
Savelli SL; Roubey RAS; Kitzmiller KJ; Zhou D; Nagaraja HN; Mulvihill E; Barbar-Smiley F; Ardoin SP; Wu YL; Yu CY
Front Immunol; 2019; 10():885. PubMed ID: 31134052
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome.
Iwaniec T; Kaczor MP; Celińska-Löwenhoff M; Polański S; Musiał J
Thromb Res; 2017 May; 153():90-94. PubMed ID: 28363116
[TBL] [Abstract][Full Text] [Related]
19. Influence of antiphospholipid antibody levels and type on thrombotic manifestations: results from the Serbian National Cohort Study.
Stojanovich L; Markovic O; Marisavljevic D; Elezovic I; Ilijevski N; Stanisavljevic N
Lupus; 2012 Mar; 21(3):338-45. PubMed ID: 21993381
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.
Tektonidou MG; Laskari K; Panagiotakos DB; Moutsopoulos HM
Arthritis Rheum; 2009 Jan; 61(1):29-36. PubMed ID: 19116963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
